Fibrin degradation product: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +) |
||
Line 16: | Line 16: | ||
{{CMG}} | {{CMG}} | ||
'''''Synonyms and Keywords:''''' FDP | '''''Synonyms and Keywords:''''' FDP | ||
Line 64: | Line 64: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] |
Latest revision as of 02:41, 9 August 2012
Fibrin degradation product | |
Principles of D-dimer testing |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and Keywords: FDP
Overview
Fibrin degradation products are formed during the metabolism of fibrinogen and fibrin via plasmin. Fibrin degradation product (FDPs) are components of the blood produced by clot degeneration.[1]
Reference Range | |
Fribin Degradation Products | < 1 mg/l |
D-Dimers | 20-400 ug/l |
Differential Diagnosis
In alphabetical order. [2] [3]
Increased
- Bladder carcinoma
- Contact with body-foreign surfaces
- Disseminated Intravascular Coagulation (DIC)
- Drugs
- False positive, if Rheumatoid factor is present
- Fibrinolytic therapy
- Postoperative
- Pulmonary Embolism
- Release of plasmin from plasminogen-rich organs (lungs, pancreas, prostate)
- Severe Liver Disease
- Subdural hematomas
- Thromboses
- Tumor
- Venous and arterial thrombotic events
See also
External links
References
- ↑ Gaffney PJ, Edgell T, Creighton-Kempsford LJ, Wheeler S, Tarelli E (1995). "Fibrin degradation product (FnDP) assays: analysis of standardization issues and target antigens in plasma". Br. J. Haematol. 90 (1): 187–94. PMID 7786784.
- ↑ Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
- ↑ Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X